Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Vensana Capital is a venture capital and growth equity investment firm founded in 2019 by Kirk Nielsen and Justin Klein. The firm operates from offices in Minneapolis, Minnesota, and Washington, D.C. Vensana Capital is dedicated to partnering with entrepreneurs to transform healthcare through innovations in medical technology. The firm has established itself as a key player in the medtech sector, focusing exclusively on development and commercial-stage companies.
Currently, Vensana Capital manages approximately $1 billion in assets under management (AUM), including a $425 million third fund. The firm has built a diverse portfolio of 20 companies, demonstrating its commitment to supporting innovative healthcare solutions. Notable milestones include the successful IPO of portfolio company CVRx and the acquisition of Vesper Medical by Philips. Vensana Capital's approach combines capital investment with operational, clinical, and business development expertise, ensuring that portfolio companies receive comprehensive support.
Vensana Capital invests primarily in development and commercial-stage companies within the medtech sector. Their investment strategy encompasses a range of focus areas, including medical devices, diagnostics, data science, drug delivery, digital health, life science tools, and tech-enabled services. The firm typically makes investments ranging from $15 million to $50 million per company, allowing them to support companies at various stages of growth.
The firm targets companies that can establish new clinical standards of care and enhance healthcare efficiency, accessibility, and cost-effectiveness. Vensana Capital's investment thesis emphasizes the belief that medtech innovation can significantly improve healthcare outcomes while reducing costs. They seek entrepreneurs who are not only looking for capital but also value operational and clinical support to build successful medtech companies.
Vensana Capital's portfolio includes a diverse array of companies focused on advancing medical technology. Notable portfolio companies include:
In addition to these, Vensana Capital has supported companies like PhaseBio Pharmaceuticals and Senseonics, both of which have gone public. The firm has also been involved in several acquisitions, including Cartiva, CV Ingenuity, and Intact Vascular, showcasing its active role in the medtech investment landscape.
Justin Klein, MD, JD: Co-founder and Managing Partner. Justin has a background as a former partner at NEA, where he led medical technology investments. His board roles include companies such as Apella and Senseonics.
Kirk Nielsen: Co-founder and Managing Partner. Kirk previously served as a managing director at Versant Ventures and has extensive experience in medtech, having led investments in companies like Inari Medical and Cameron Health.
Amrinder Singh: Partner. Amrinder was a Senior Investment Director at Medtronic Ventures, focusing on medical device and diagnostics investments. He holds board roles at iVEAcare and Luna Diabetes.
Maria Berkman, MD: Partner. Maria has held leadership positions at Broadview Ventures and Longview Ventures, with board experience in cardiovascular and stroke-focused medtech companies.
Greg Banker: Partner. Greg was previously the Director of Strategic Market Development at Vertiflex, which was acquired by Boston Scientific. He has significant experience in medtech market assessment.
Ross (Rusty) Segan: Venture Partner. Rusty has a background in medtech operations and has held various board roles in the industry.
To pitch Vensana Capital, founders should use the contact email provided on their website. A well-structured pitch deck is essential, highlighting the startup's technology, market opportunity, and team qualifications. While specific application forms or portals are not mentioned, a clear and concise presentation of the business is crucial.
Response times may vary, but founders can expect a thorough evaluation of their proposals. Warm introductions are beneficial, as they can facilitate initial discussions and increase the likelihood of engagement.
Vensana Capital has established the Vensana Innovation (VI) program, an innovation engine dedicated to launching and building medtech companies. This program pairs capital with a dedicated team that provides technical, clinical, commercial, and business development expertise.
Eligibility for the Vensana Innovation program includes companies in the medtech sector that are looking for comprehensive support beyond capital. Interested founders can apply through the firm's website for more information on the program and its offerings.
In 2025, Vensana Capital successfully closed its $425 million Fund III, aimed at backing breakthrough medical technology companies. This fund will enable the firm to continue its focus on supporting innovative startups in the medtech sector.
Recent portfolio highlights include the IPO of SpyGlass Pharma, which has garnered attention for its advancements in ophthalmology. Additionally, funding rounds for Ventaris Surgical and Apella have been announced, showcasing Vensana's active engagement with its portfolio companies.
What are Vensana Capital's investment criteria?
Vensana Capital focuses on development and commercial-stage companies in the medtech sector, particularly in medical devices, diagnostics, and digital health. They typically invest between $15 million and $50 million per company.
How can I pitch to Vensana Capital?
Founders can pitch Vensana Capital by visiting their website and using the contact email provided. A well-prepared pitch deck should include details about the technology, market opportunity, and team.
What makes Vensana Capital different from other investors?
Vensana Capital differentiates itself through its exclusive focus on medtech and its commitment to providing operational, clinical, and business development support to portfolio companies.
What is the geographic scope of Vensana Capital's investments?
The firm primarily invests in companies based in the United States but is open to global medtech opportunities.
What is the decision timeline for investments?
While specific timelines are not disclosed, Vensana Capital operates on a rolling application cycle, allowing for ongoing evaluations of potential investments.
What kind of post-investment involvement can founders expect?
Vensana Capital actively engages with its portfolio companies, providing support in operational, clinical, and business development areas to help them succeed in the competitive medtech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.